Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Multicenter Study to Compare the Safety and Efficacy of 166Ho-DOTMP Plus Melphalan to Melphalan Alone as Conditioning for Autologous Peripheral Blood Stem Cell Transplant in Subjects With Primary Refractory Multiple Myeloma

NCT00083564 is registered in ClinicalTrials.gov with Poniard Pharmaceuticals as lead sponsor.

NCT NCT00083564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00083564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Multicenter Study to Compare the Safety and Efficacy of 166Ho-DOTMP Plus Melphalan to Melphalan Alone as Conditioning for Autologous Peripheral Blood Stem Cell Transplant in Subjects With Primary Refractory Multiple Myeloma
Lead sponsor
Poniard Pharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2004
Completion date
Not reported
Enrollment
240
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma